Drug Trials Snapshots

MODEYSOdordaviprone08/06/2025To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapModeysoSEPHIENCEsepiapterin07/28/2025To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted dietSephienceANZUPGOdelgocitinib07/23/2025To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate responseAnzupgoEKTERLYsebetralstat7/3/2025To treat acute attacks of hereditary angioedemaEkterlyANDEMBRYgaradacimab6/17/2025To prevent attacks of hereditary angioedemaAndemryIBTROZItaletrectinib6/11/2025To treat locally advanced or metastatic ROS1-positive non-small cell lung cancerIbtroziENFLONSIAclesrovimab6/9/2025To treat respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infantsEnflonsiaEMRELIStelisotuzumab vedotin-tllv5/14/2025To treat adult patients with locally advanced or metastatic non-squamous non-small cell lung cancerEmrelisTRYPTYRacoltremon5/28/2025To treat the signs and symptoms of dry eye diseaseTryptyrIMAAVYnipocalimab-aahu4/29/2025To treat generalized myasthenia gravisImaavyAVMAPKI FAKZYNJA CO-PACKavutometinib; defactinib4/28/2025To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapyAvmapki Fakzynja Co-PackPENPULIMAB-KCQXpenpulimab-kcqx4/23/2025To treat adult patients with metastatic or recurrent, locally advanced non-keratinizing nasopharyngeal cancerpenpulimab-kcqxVANRAFIAatrasentan4/2/2025To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionVanrafiaQFITLIAfitusiran3/28/2025To prevent or reduce the frequency of bleeding episodes in hemophilia A or BQfitliaBLUJEPAgepotidacin3/25/2025For the treatment of female adult and pediatric patients 12 years of age and olderBlujepaROMVIMZAvimseltinib2/17/2025To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidityRomvimzaGOMEKLImirdametinib2/11/2025For treatment in adults and children 2 years of age and older with neurofibromatosis type 1 (NF1)GomekliJOURNAVXsuzetrigine1/30/2025For the treatment of moderate to severe acute pain in adultsJournavxGRAFAPEXtreosulfan1/21/2025For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patientsGrafapexALYFTREKvanzacaftor/tezacaftor/deutivacaftor12/20/2024For the treatment of cystic fibrosis (CF) in patients 6 years of age and olderAlyftrekALHEMOconcizumab12/20/2024For routine prophylaxis to prevent bleeding episodes in hemophilia A and BAlhemoIOMERVUiomeprol11/27/2024Is used during an arteriogram to visualize blood vessels in adult and pediatric patientsIomervuRAPIBLYKlandiolol hydrochloride11/22/2024For short-term reduction of ventricular rate in adults with supraventricular tachycardia.RapiblykTRYNGOLZAolezarsen12/19/2024To treat familial chylomicronemia syndromeTryngolzaCOBENFYxanomeline tartrate and trospium chloride9/26/2024To treat schizophreniaCobenfyATTRUBYacoramidis11/22/2024To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosisAttrubyITOVEBIinavolisib10/10/2024To treat locally advanced or metastatic breast cancerItovebiHYMPAVZImarstacimab10/11/2024To prevent or reduce bleeding episodes related to hemophilia A or BHympavziLAZCLUZElazertinib8/19/2024To treat non-small cell lung cancerLazcluzeMIPLYFFAarimoclomol9/20/2024To treat Niemann-Pick disease type CMiplyffaAQNEURSAlevacetylleucine9/24/2024Treatment of Niemann-Pick disease type CAqneursaNIKTIMVOaxatilimab-csfr8/14/2024To treat chronic graft-versus-host disease (cGVHD)NiktimvoEBGLYSSlebrikizumab-lbkz9/13/2024An interleukin-13 antagonist indicated for the treatment of adult and pediatric patients 12 years of age and olderEbglyssLUMISIGHTpegulicianine4/17/2024To use as an optical imaging agent for the detection of cancerous tissueLumisightMIEBOperfluorohexyloctane ophthalmic solution5/18/2023Treatment for patients with the signs and symptoms of dry eye disease (DED)MieboAGAMREEvamorolone10/26/2023Treatment of Duchenne muscular dystrophyAgamreeAMVUTTRAvutrisiran6/13/2022To treat polyneuropathy of hereditary transthyretin-mediated amyloidosisAmvuttraANKTIVAnogapendekin alfa inbakicept-pmnl4/22/2024To treat a subtype of non-muscle invasive bladder cancer (NMIBC), called carcinoma in situ (CIS)AnktiviaAPHEXDAmotixafortide9/8/2023To mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myelomaAphexdaAUGTYROrepotrectinib11/15/2023To treat ROS1-positive non-small cell lung cancerAugtyroBEYFORTUSnirsevimab7/17/2023Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease.BeyfortusBIMZELXbimekizumab-bkzx10/17/2023Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.BimzelxBIZENGRIzenocutuzumab-zbco12/4/2024To treat non-small cell lung cancer and pancreatic adenocarcinomaBizengriBRENZAVVY bexagliflozin1/20/2023To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exerciseBrenzavvyBRIUMVIublituximab-xiiy12/28/2022To treat relapsing forms of multiple sclerosisBriumviCAMZYOSmavacamten4/28/2022To treat certain classes of obstructive hypertrophic cardiomyopathyCamzyosCIBINQOabrocitinib1/14/2022Treatment of adults with refractory, moderate-to-severe atopic dermatitisCibinqoCOLUMVIglofitamab-gxbm6/15/2023Treatment of diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapyColumviCRENESSITYcrinecerfont12/13/2024To treat classic congenital adrenal hyperplasia CrenessityDATROWAYdatopotamab deruxtecan-dlnk1/17/2025To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic diseaseDatrowayDAXXIFYdaxibotulinumtoxin A9/7/2022To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity.DaxxifyDAYBUEtrofinetide3/12/2023To treat Rett syndrome.DaybueDEFENCATHtaurolidine, heparin11/15/2023To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.DefencathDUVYZATgivinostat3/21/2024Treatment of Duchenne muscular dystrophy in individuals aged 6 years and olderDuvyzatELAHEREmirvetuximab soravtansine-gynx11/14/2022To treat patients with recurrent ovarian cancer that is resistant to platinum therapyElahereELFABRIOpegunigalsidase alfa-iwx5/9/2023An enzyme replacement therapy that is used for the treatment of Fabry disease in adult patients.ElfabrioELREXFIOelranatamab-bcmm8/14/2023To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapyElrexfioELUCIREMgadopiclenol9/21/2022To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the bodyEluciremENJAYMOsutimlimab-jome2/4/2022To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin diseaseEnjaymoENSACOVEensartinib12/18/2024To treat non-small cell lung cancerEnsacoveEPKINLYepcoritamab-bysp5/19/2023To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapyEpkinlyEXBLIFEPcefepime and enmetazobactam2/22/2024For the treatment of patients 18 years and older with complicated urinary tract infections (cUTI)ExblifepEXXUAgepirone9/22/2023Treatment of major depressive disorderExxuaFABHLATAiptacopan12/5/2023Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)FabhlataFILSPARIsparsentan2/17/2023To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionFilspariFILSUVEZbirch triterpenes12/18/2023To treat wounds associated with dystrophic and junctional epidermolysis bullosaFilsuvezFLYRCADOflurpiridaz F 18 Injection9/27/2024A radioactive diagnostic drug to evaluate for myocardial ischemia and infarctionFlyrcadoFRUZAQLAfruquintinib11/8/2023To treat refractory, metastatic colorectal cancerFruzaqlaIMJUDOtremelimimab-actl10/21/2022To treat unresectable hepatocellular carcinomaImjudoINPEFAsotagliflozin5/26/2023Treatment of heart failureInpefaIQIRVOelafibranor6/10/2024To treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCAiqirvoIZERVAYavacincaptad pegol intravitreal solution8/4/2023To treat geographic atrophy secondary to age-related macular degenerationIzervayJAYPIRCApirtobrutinib1/27/2023To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorJaypircaJOENJAleniolisib3/24/2023Treatment of activated phosphoinositide 3-kinase delta syndrome.JoenjaJESDUVROQdaprodustat2/1/2023Treatment of anemia caused by chronic kidney disease for adults on dialysis for at least four months.JesduvroqKIMMTRAKtebentafusp1/25/2022To treat unresectable or metastatic uveal melanomaKimmtrakKISUNLAdonanemab-azbt7/2/2024To treat people with Alzheimer’s diseaseKisunlaKRAZATIadagrasib12/12/2022Prescription medicine used to treat adult patients with non-small cell lung cancerKrazatiLAMZEDEvelmanase alfa-tycv2/16/2023To treat non-central nervous system manifestations of alpha-mannosidosisLamzedeLEQEMBIlecanemab-irmb1/6/2023Treatment of Alzheimer’s diseaseLeqembiLEQSELVIdeuruxolitinib7/25/2024Indicated for the treatment of adults with severe alopecia areata (AA).LeqselviLETYBOletibotulinumtoxinA2/29/2024To temporarily improve the appearance of moderate-to-severe glabellar linesLetyboLIVDELZIseladelpar8/14/2024To treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.LivdelziLUNSUMIOmosunetuzumab-axgb12/22/2022To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphomaLunsumioLYTGOBIfutibatinib9/30/2022To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangementsLytgobiMOUNJAROtirzepatide5/13/2022To improve blood sugar control in diabetes, in addition to diet and exerciseMounjaroNEMLUVIOnemolizumab-ilto8/12/2024To treat prurigo nodularisNemluvioNEXOBRIDanacaulase-bcdb12/28/2022To remove charred tissue in adults with deep second degree and/or third degree burns from heat sourcesNexobridNGENLAsomatrogon-ghla6/27/2023Treatment of growth failure due to inadequate secretion of endogenous growth hormoneNgenlaOGSIVEOnirogacestat11/27/2023To treat adults with progressing desmoid tumors who require systemic treatmentOgsiveoOHTUVAYREensifentrine6/26/2024For the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.OhtuvayreOJEMDAtovorafenib4/23/2024To treat certain types of brain tumors (cancers) called gliomas in patients 6 months and olderOjemdaOJJAARAmomelotinib9/15/2023to treat a rare type of bone marrow disorder called myelofibrosis (MF) in adults with anemiaOjjaaraOMLONTIoomidenepag isopropyl9/22/2022Reduces elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertensionOmlontiOPDUALAGnivolumab and relatlimab-rmbw3/18/2022Treatment of adults and pediatric patients 12 years of age or older with a type of skin cancer called melanoma that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic).OpdualagORLYNVAHsulopenem etzadroxil and probenecid10/25/2024Treatment of uncomplicated urinary tract infections (uUTI)OrlynvahORSERDUelacestrant1/27/2023To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.OrserduPAXLOVIDnirmatrelvir, ritonavir5/25/2023To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19PaxlovidPIASKYcrovalimab-akkz6/20/2024Treatment of paroxysmal nocturnal hemoglobinuriaPiaskyPLUVICTOlutetium Lu 177 vipivotide tetraxetan3/23/2022To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapiesPluvictoPOMBILITIcipaglucosidase alfa-atga9/28/2023the treatment of adult patients with late-onset Pompe disease (LOPD)Pombiliti OpfoldaPOSLUMAflotufolastat F 185/25/2023To detect specific cancer lesions in males with prostate cancerPoslumaPYRUKYNDmitapivat2/17/2022Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiencyPyrukyndQALSODYtofersen4/25/2023Treatment of amyotrophic lateral sclerosis in adults who have a SOD1 gene mutationQalsodyQUVIVIQdaridorexant1/7/2022Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.QuvivqRELYVRIOsodium phenylbutyrate and taurursodiol9/29/2022To treat amyotrophic lateral sclerosis (ALS)RelyvrioREVUFORJ revumenib11/15/2024To treat relapsed or refractory acute leukemiaRevuforjREZDIFFRAresmetirom3/14/2024To treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.RezdiffraREZLIDHIAolutasidenib12/1/2022Treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutationRezlidhiaZAYOrezafungin for injection3/22/2023To treat candidemia and invasive candidiasisRezzayoRIVFLOZAnedosiran9/29/2023To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney functionRivflozaROLVEDONeflapegrastim9/9/2022To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropeniaRolvedonRYSTIGGOrozanolixizumab-noli6/26/2023To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positiveRystiggoRYTELOimetelsta6/6/2024to treat a condition called low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults with anemiaRyteloRYZNEUTAefbemalenograstim alfa-vuxw11/11/2023To treat neutropeniaRyzneutaSKYCLARYSomaveloxolone2/28/2023To treat Friedrich’s ataxiaSkyclarysSOFDRAsofpironium bromide6/18/2024An anticholinergic antiperspirant approved for primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.SofdraSOHONOSpalovarotene8/16/2023To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressivaSohonosSOTYKTUdeucravacitinib9/9/2022To treat moderate-to-severe plaque psoriasisSotyktuSPEVIGOspesolimab-sbzo9/1/2022To treat generalized pustular psoriasis flaresSpevigoSUNLENCAlenacapavir12/22/2022To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerationsSunlencaTALVEYtalquetamab-tgvs8/10/2023To treat a form of blood cancer called multiple myelomaTalveyTECVAYLI teclistamab-cqyv10/25/2022To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapyTecvayliTERLIVAZterlipressin9/14/2022Treatment to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney functionTerlivazTEVIMBRAtislelizumab-jsgr3/14/2024To treat unresectable or metastatic esophageal squamous cell carcinomaTevimbraTRUQAPcapivasertib11/16/2023To treat breast cancer that meets certain disease criteriaTruqapTZIELDteplizumab-mzwv11/17/2022Used to delay the onset of type 1 diabetes in children and adults who are at high risk for type 1 diabetesTzieldUNLOXCYTcosibelimab-ipdl12/13/2024To treat cutaneous squamous cell carcinomaUnloxcytVABYSMOfaricimab-svoa1/28/2022To treat neovascular (wet) aged-related macular degeneration and diabetic macular edemaVabysmoVEOZAHfezolinetant5/12/2023To treat moderate to severe hot flashes caused by menopauseVeozahVIVJOAoteseconazole4/26/2022To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potentialVivjoaVONJOpacritinib2/28/2022To treat adult patients with a rare type of bone marrow disorder called myelofibrosis with platelet counts below 50,000/µL.VonjoVOQUEZNAvonoprazan fumarate, amoxicillin5/3/2022Treatment of Helicobacter pylori infectionVoqueznaVORANIGOvorasidenib8/6/2024Treatment of Grade 2 astrocytoma or oligodendrogliomaVoranigoVOYDEYAdanicopan3/29/2024To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuriaVoydeyaVTAMAtapinarof12/7/2023Treatment of plaque psoriasisVtamaVYLOYzolbetuximab-clzb10/18/2024To treat gastric or gastroesophageal junction adenocarcinomaVyloyWAINUAeplontersen12/21/2023To treat polyneuropathy of hereditary transthyretin-mediated amyloidosisWainuaWINREVAIRsotatercept-csrk3/26/2024For the treatment of adults with pulmonary arterial hypertensionWinrevairXACDUROsulbactam for injection; durlobactam for injection5/23/2023Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complexXacduroXDEMVYlotilaner ophthalmic solution7/24/2023To treat Demodex blepharitis, a type of eyelid infection. xdemvyXENOVIEWxenon Xe 129 hyperpolarized12/8/2023Evaluation of lung ventilation in adults and pediatric patientsXenoviewXENPOZYMEolipudase alfa-rpcp8/31/2023To treat Acid Sphingomyelinase DeficiencyXenpozymeXOLREMDImavorixafor4/26/2024For the treatment of adults and adolescents over the age of 12 years with WHIM (Warts, Hypogammaglobulinemia, Infection, and Myelokathexis) syndromeXolremdiYORVIPATHpalopegteriparatide8/9/2024To treat hypoparathyroidismYorvipathZAVZPRETzavegepant3/9/2023To treat migraineZavzpretZELSUVMIberdazimer1/5/2024Treatment of molluscum contagiosumZelsuvmiZEVTERAceftobiprole medocaril sodium for injection4/3/2024Treatment of certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumoniaZevteraZIIHERAzanidatamab-hrii11/20/2024To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancerZiiheraZILBRYSQzilucoplan10/17/2023To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positiveZilbrysqZTALMYganaxolone3/18/2023To treat seizures in cyclin-dependent kinase-like 5 deficiency disorderZtalmy